Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Exane BNP Paribas Downgrades Chevron to Underperform

Exane BNP Paribas Downgrades Chevron to Underperform

Exane BNP Paribas analyst Lucas Herrmann downgrades Chevron (NYSE:CVX) from Neutral to Underperform.

byBenzinga Newsdesk

December 14, 2022

1 minute read

Exane BNP Paribas analyst Lucas Herrmann downgrades Chevron (NYSE:CVX) from Neutral to Underperform.

Analyst Ratings

Expert Ratings for TFI International

By Benzinga Insights

October 9, 4:00 PM

Within the last quarter, TFI International (NYSE:TFII) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

TFII

Goodness Growth Reports 16% YoY Revenue Growth In Q1, Progress Regarding New York Exit

By Nina Zdinjak

May 8, 7:25 AM

Cannabis companyÂ Goodness Growth Holdings, Inc.Â (CSE:GDNS) (OTCQX:GDNSF) reported financial results Tuesday for its first quarter ended March 31, 2024,…

CSE:GDNS

BioAffinity Technologies, Subsidiary Oncoselect Therapeutics, Has Been Granted U.S. Patent Number 11,590,233 Titled “Porphyrin Compounds And Compositions Useful For Treating Cancer”

By Happy Mohamed

February 28, 12:34 PM

https://ppubs.uspto.gov/pubwebapp/external.html?q=(11590233).pn

BIAF

This Apple Option Saw Massive Surge In Volumes: What Could Have Happened?

By Bhavik Nair

December 6, 7:55 AM

In the last five days, Apple Inc (NASDAQ: AAPL) shares have risen 1.65% but failed to breach the $150 level. Options data shows that the 150-strike Call option with the Dec. 9 expiry has seen the maximum volume at 118,605, according to Barchart data.

AAPL

Exane BNP Paribas Downgrades Chevron to Underperform

Related Posts

Expert Ratings for TFI International

Goodness Growth Reports 16% YoY Revenue Growth In Q1, Progress Regarding New York Exit

BioAffinity Technologies, Subsidiary Oncoselect Therapeutics, Has Been Granted U.S. Patent Number 11,590,233 Titled “Porphyrin Compounds And Compositions Useful For Treating Cancer”

This Apple Option Saw Massive Surge In Volumes: What Could Have Happened?